ReviewNature reviews. Clinical oncology2011
Tumor control versus adverse events with targeted anticancer therapies.
Review in Nature reviews. Clinical oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Systematic Review of the Side Effects Associated With Anti-HER2-Targeted Therapies Used in the Treatment of Breast Cancer, on Behalf of the EORTC Quality of Life Group.Targeted oncology · 2016Pooled it
- Mass spectrometry-based serum and plasma peptidome profiling for prediction of treatment outcome in patients with solid malignancies.The oncologist · 2014Pooled it
- Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2013Pooled it
- Red blood cell-conjugated biomimetic nanomedicine for enhanced therapy of non-small cell lung cancer.Theranostics · 2026Article
- Article
- Advances in VEGFR Inhibitors: A Comprehensive Review of Novel Anticancer Agents.Anti-cancer agents in medicinal chemistry · 2025Review
- The Selective in vitro Cytotoxicity ofInternational journal of nanomedicine · 2025Article
- Trajectories of depression and predictors in lung cancer patients undergoing chemotherapy: growth mixture model.BMC psychiatry · 2024Article
- Article
- Article
- Towards UGT1A1 guided irinotecan dosing.European journal of human genetics : EJHG · 2023Article
- Personalized Targeted Therapeutic Strategies against Oral Squamous Cell Carcinoma. An Evidence-Based Review of Literature.International journal of nanomedicine · 2022Review
- Cross-Resistance Among Sequential Cancer Therapeutics: An Emerging Issue.Frontiers in oncology · 2022Review
- TLR4 and TLR9 polymorphism: Probable role in susceptibility among the population of Bihar for Indian visceral leishmaniasis.Innate immunity · 2021Article
- Discovery of new fluorescent thiazole-pyrazoline derivatives as autophagy inducers by inhibiting mTOR activity in A549 human lung cancer cells.Cell death & disease · 2020Article
- Synthesis and biological evaluation of a new series of 1-aryl-3-[4-(pyridin-2-ylmethoxy)phenyl]urea derivatives as new anticancer agents.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2020Article
- Design, Synthesis and Biological Evaluation of a New Series of 1-Aryl-3-{4-[(pyridin-2-ylmethyl)thio]phenyl}urea Derivatives as Antiproliferative Agents.Molecules (Basel, Switzerland) · 2019Article
- State of the art of overcoming efflux transporter mediated multidrug resistance of breast cancer.Translational cancer research · 2019Review
- Stomatitis And Everolimus: A Review Of Current Literature On 8,201 Patients.OncoTargets and therapy · 2019Article
- Life-threatening Hyperkalemia Associated with Axitinib Treatment in Patients with Recurrent Renal Carcinoma.Internal medicine (Tokyo, Japan) · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The advent of targeted anticancer therapies over the past few decades has reinvigorated the field of cancer therapeutics, with the promise of increased cancer cure rates accompanied by decreased toxicity. But, has that promise been fulfilled? The short answer is definitely 'no', both because of disappointing tumor responses and unexpectedly high toxicity, as well as the extremely high financial cost of these agents. However, failing to completely fulfill initial promise does not mean that targeted therapies should be abandoned. Increased progression-free survival might ultimately lead to increased overall survival, and targeted therapies have changed the course of cancers such as breast, lung and renal. Therefore, we would argue that despite some disappointments, targeted therapies have a vital role in future cancer treatment. This Review will discuss the positives and negatives of targeted agents, and propose a way to optimize their use and development to ensure proper personalized cancer medicine that tailors not only the anticancer treatment, but also the antitoxicity strategies, to achieve the best outcome for the patient in terms of both quality and quantity of life.
Indexed as
Identifiers
22182972What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.